Kidney Transplant Rejection Pipeline Summary

DelveInsight’s, “Kidney Transplant Rejection - Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Kidney Transplant Rejection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Kidney Transplant Rejection: Understanding

Kidney Transplant Rejection: Overview

Kidney transplant rejection occurs when the recipient’s immune system recognizes the donor kidney as foreign and mounts an immune attack, threatening graft survival. It can present as acute rejection, typically within months, driven by T-cell-mediated or antibody-mediated injury and responsible for a significant portion of early graft failures. Chronic rejection, developing after the first year, leads to progressive scarring such as interstitial fibrosis, tubular atrophy, and transplant glomerulopathy, contributing to many late allograft losses. Rare forms like hyperacute and accelerated rejection occur rapidly after transplant due to preformed antibodies. Despite advances in immunosuppression, rejection remains a major challenge to long-term kidney transplant success.

Kidney transplant rejection typically presents with flu-like symptoms such as fever, chills, body aches, and pronounced fatigue, reflecting early immune activation. Patients may notice tenderness or pain over the transplanted kidney, often accompanied by reduced urine output. Sudden weight gain due to fluid retention and swelling in the legs or ankles are common physical signs. Rising blood pressure and increasing creatinine levels indicate declining kidney function. Additional symptoms like new-onset proteinuria or graft-site discomfort can further signal underlying antibody- or T-cell-driven rejection.

Kidney transplant rejection occurs when the immune system detects the donor kidney as foreign, activating T-cell- or antibody-mediated pathways. Antibody-mediated rejection (ABMR) is the leading cause, driven by donor-specific antibodies that trigger complement activation, endothelial injury, and chronic graft damage. T-cell-mediated rejection (TCMR) involves cytotoxic T-cell activation and inflammation, with regulatory T-cell and B-cell imbalances further increasing risk. Key contributors include nonadherence to immunosuppressive therapy, HLA mismatching, prior episodes of rejection, deceased-donor grafts, younger recipient age, and delayed graft function.

Kidney transplant rejection is diagnosed through clinical evaluation, lab findings, and biopsy confirmation using the Banff classification to distinguish acute and chronic injury. Rising creatinine typically prompts a biopsy, which identifies features of T-cell- or antibody-mediated rejection such as tubulitis, inflammation, C4d staining, or donor-specific antibodies. Non-invasive tests like urine biomarkers and donor-derived cell-free DNA support early detection of immune activity. Imaging tools including contrast-enhanced ultrasound or MRI help reveal perfusion changes consistent with graft injury.

Kidney transplant rejection treatment aims to quickly suppress immune activation, guided by biopsy-confirmed type. T-cell-mediated rejection (TCMR) is typically managed with high-dose corticosteroids, with lymphocyte-depleting agents used when steroid response is inadequate. Antibody-mediated rejection (ABMR) requires a multimodal approach combining antibody-removal therapies, immunoglobulin, and B-cell or complement-targeting agents, with emerging biologics used for resistant cases.

"Kidney Transplant Rejection- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kidney Transplant Rejection pipeline landscape is provided which includes the disease overview and Kidney Transplant Rejection treatment guidelines. The assessment part of the report embraces, in depth Kidney Transplant Rejection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kidney Transplant Rejection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Kidney Transplant Rejection R&D. The therapies under development are focused on novel approaches to treat/improve Kidney Transplant Rejection.

Kidney Transplant Rejection Emerging Drugs Chapters

This segment of the Kidney Transplant Rejection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Kidney Transplant Rejection Emerging Drugs

• Felzartamab: Biogen

Felzartamab is a human monoclonal antibody being developed by Biogen for the treatment of kidney transplant rejection, particularly antibody-mediated rejection (AMR). It targets CD38, a cell surface protein highly expressed on plasma cells, which are responsible for producing donor-specific antibodies that can damage the transplanted kidney. By binding to CD38, felzartamab depletes pathogenic plasma cells through immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). This reduction in antibody-producing cells helps lower donor-specific antibody levels, mitigate immune-mediated graft injury, and preserve transplanted kidney function. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Kidney Transplant Rejection.

• Tegoprubart: Eledon Pharmaceuticals

Tegoprubart is an investigational immunosuppressive therapy developed by Eledon Pharmaceuticals that works as a novel anti-CD40L antibody to modulate the immune response and prevent the body from rejecting a transplanted kidney. It targets the CD40/CD40L costimulatory pathway, a key driver of immune activation in allograft rejection, potentially offering effective immunosuppression with a differentiated safety profile compared with traditional regimens. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Kidney Transplant Rejection.

• BPC2003: BioPhoenix Co., Ltd.

BPC2003 is an investigational immunomodulatory therapy, which is designed to regulate the immune response by suppressing the activation and proliferation of alloreactive T lymphocytes, which are the primary mediators of graft rejection. Through its targeted immunosuppressive mechanism, BPC2003 aims to reduce immune-mediated injury to the transplanted kidney, promote long-term graft survival, and preserve transplant function while potentially minimizing the broader immune suppression associated with conventional therapies. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Kidney Transplant rejection.

Further product details are provided in the report……..

Kidney Transplant Rejection: Therapeutic Assessment

This segment of the report provides insights about the different Kidney Transplant Rejection drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Kidney Transplant Rejection

There are approx. 18+ key companies which are developing the therapies Kidney Transplant Rejection. The companies which have their Kidney Transplant Rejection drug candidates in the most advanced stage, i.e. Phase III include, Biogen, and others.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Kidney Transplant Rejection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kidney Transplant Rejection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kidney Transplant Rejection drugs.

Kidney Transplant Rejection Report Insights

• Kidney Transplant Rejection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Kidney Transplant Rejection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Kidney Transplant Rejection drugs?
• How many Kidney Transplant Rejection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kidney Transplant Rejection?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kidney Transplant Rejection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Kidney Transplant Rejection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biogen
• Eledon Therapeutics
• BioPhoenix Co., Ltd.
• Veloxis Pharmaceuticals

Key Products

• Felzartamab
• Tegoprubart
• BPC2003
• VEL-101